Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer

Authors

Manik Amin, Washington University School of Medicine in St. Louis
Monica Desai, Washington University School of Medicine in St. Louis
Kathryn Trinkaus, Washington University School of Medicine in St. Louis
Amberly Brown, Washington University School of Medicine in St. Louis
Andrea Wang-Gillam, Washington University School of Medicine in St. Louis
Benjamin Tan, Washington University School of Medicine in St. Louis
Joel Picus, Washington University School of Medicine in St. Louis
Steven Sorscher, Wake Forest University
Maureen Highkin, Washington University School of Medicine in St. Louis
Kim Lears, Washington University School of Medicine in St. Louis
Albert C. Lockhart, University of Miami

Journal

Journal Gastrointestinal Oncology

Publication Date

6-1-2019

Volume

10

Issue

3

First Page

412

Last Page

420

Document Type

Open Access Publication

DOI

10.21037/jgo.2019.02.01

Rights and Permissions

Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. J Gastrointest Oncol 2019;10(3):412-420. doi: 10.21037/jgo.2019.02.01

Recommended Citation

Amin, Manik; Desai, Monica; Trinkaus, Kathryn; Brown, Amberly; Wang-Gillam, Andrea; Tan, Benjamin; Picus, Joel; Sorscher, Steven; Highkin, Maureen; Lears, Kim; and Lockhart, Albert C., "Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer." Journal Gastrointestinal Oncology. 10, 3. 412 - 420. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9921